Business Context and Reporting Period
Company: Incyte Genomics, Inc. (formerly Incyte Pharmaceuticals, Inc.)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2000
Business Overview: The Company designs, develops, and markets genomic information-based tools, including database products, software, microarray-based gene expression services, and genomic reagents. In June 2000, the Company changed its name to Incyte Genomics, Inc.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2000 | Six Months Ended June 30, 2000 |
|---|---|---|
| Revenues | $46.0 million | $86.8 million |
| Net Loss | $(6.6) million | $(14.8) million |
| Net Loss Per Share (Basic & Diluted) | $(0.21) | $(0.47) |
| Operating Cash Flow (6 months) | $27.5 million | |
| Cash and Cash Equivalents (June 30, 2000) | $438.1 million | |
| Total Assets (June 30, 2000) | $876.6 million | |
| Total Liabilities (June 30, 2000) | $274.7 million | |
| Convertible Subordinated Notes | $200.0 million (issued Feb 2000) |
Liquidity: As of June 30, 2000, the Company held $681.9 million in cash, cash equivalents, and marketable securities, a significant increase from $66.9 million at year-end 1999, driven by a $398.3 million private equity offering and $196.8 million in convertible note proceeds in February 2000.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 21% year-over-year for the quarter ($46.0M vs. $37.9M) and 15% for the six-month period ($86.8M vs. $75.5M). Growth was driven by new database agreements, new products (expression databases, isSNP), and increased custom genomics services.
- Expense Increases: Total costs and expenses rose significantly to $60.4 million (quarter) and $116.6 million (six months) compared to $45.6 million and $85.2 million in 1999.
- R&D: Increased to $45.4 million (quarter) due to bioinformatics, SNP discovery, and microarray production efforts.
- SG&A: Increased to $15.0 million (quarter) due to sales/marketing expansion and legal expenses (~$1.5M) related to patent litigation.
- Interest Income: Net interest and other income surged to $10.8 million (quarter) from $1.6 million in 1999, primarily due to higher cash balances from recent financings and a $5.4 million gain on the sale of a long-term investment.
- Joint Venture Accounting: The Company ceased equity method accounting for its joint venture, diaDexus, LLC, in April 2000 following a financing event that diluted the Company's influence. Consequently, no joint venture losses were recorded for the quarter ended June 30, 2000.
Guidance, Outlook, and Risks
- Outlook: Management expects to report a net loss for the full year 2000 due to continued heavy investment in sequencing, bioinformatics, SNP discovery, and e-commerce programs. The Company believes current resources are adequate for at least the next 12 months.
- Stock Split: A two-for-one stock split was approved in July 2000, with distribution scheduled for August 31, 2000. Financial statements do not reflect this split.
- Material Litigation: The Company is defending patent infringement lawsuits filed by Affymetrix, Inc. regarding microarray technology. Affymetrix seeks permanent injunctions and treble damages. The Company cannot estimate potential losses but notes substantial legal expenses and management distraction. A pretrial hearing is scheduled for November 2000.
- Accounting Changes: The Company is evaluating the impact of SAB 101 regarding non-refundable up-front fees, which may result in a charge to operations in Q4 2000 if a policy change is deemed necessary.
Investor Verification Checklist
- Litigation Exposure: Verify the status of the Affymetrix patent infringement suits and the potential impact on microarray service revenues and future licensing costs.
- Revenue Sustainability: Assess the renewal rates of database collaboration agreements and the timeline for milestone payments from drug discovery collaborations.
- Cash Burn Rate: Monitor the trajectory of R&D and SG&A expenses against the $681.9 million cash balance to determine runway without further dilution.
- Accounting Policy Impact: Confirm the final determination on SAB 101 implementation and the magnitude of any potential Q4 2000 charge.
- Debt Covenants: Review the terms of the $200 million convertible notes, specifically redemption triggers and conversion prices ($134.84/share).